Nyron J. Persaud

Cooley advised Brigit, a financial health technology company, on its definitive agreement to be acquired by Upbound Group (Nasdaq: UPBD), a technology- and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, for total consideration of up to $460 million.

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Cooley advised PetIQ (Nasdaq: PETQ), a leading pet medication, health and wellness company, on its definitive merger agreement with Bansk Group, pursuant to which Bansk Group will acquire all outstanding shares of PetIQ’s common stock for $31 per share in an all-cash transaction valued at approximately $1.5 billion.

Cooley advised CareJourney, a preeminent provider of clinically relevant healthcare data and artificial intelligence-powered analytics and insights, on its acquisition by Arcadia, a top data platform for healthcare.

Cooley advised Rooam, a contactless payment platform that integrates directly into existing point of sale systems without adding extra hardware, on its agreement to be acquired by American Express (NYSE: AXP), a globally integrated payments company providing customers with access to products, insights and experiences that enrich lives and build business success.